Clinical Trial

Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus

Study acronym: ALICIA(BY)
Recruiting
View on ClinicalTrials.gov →
Summary
to address critical gap in knowledge, providing essential data on the real-world effectiveness, safety, associated with acalabrutinib treatment in patients with CLL
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-12-03; most recent amendment 2026-07-15.
Status change: Not Yet Recruiting → Recruiting 2026-02-19
Trial Details
NCT Number NCT07288515
Lead Sponsor AstraZeneca
Conditions Chronic Lymphocytic Leukemia
Enrollment 50 participants
Start Date 2025-12-31
Primary Completion 2029-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-16